Given the rapid spread of novel coronavirus 2019 pandemic (COVID-19), confirmed COVID-19 cases have reached more than 31,000,000 worldwide with 960,000 deaths.4 Therefore, more HCT patients are at greater risk of infections and the immunopathogenesis of COVID-19 implicates a virus-driven organ damage followed by a robust inflammatory reaction involving the overexpression of several proinflammatory mediators such as IL-6, TNF and host G-CSF resulting in a cytokine storm that contributes to further vital organ compromise, multisystem dysfunction syndrome and death.5 The gene discussed is IL6; the disease is COVID-19.